What is Instant DiagnostiCX?

Instant DiagnostiCX is a 60-second saliva-based diagnostic test developed by SiMed Global for rapid point-of-care testing.

How does the saliva test work?

A saliva sample is collected and analysed by the DiagnostiCX platform, delivering results within 60 seconds without the need for a laboratory.

How long does the test take?

The test delivers results in approximately 60 seconds.

Does it require a lab?

No. The Instant DiagnostiCX test is designed for point-of-care use and requires no laboratory equipment.

Who makes Instant DiagnostiCX?

Instant DiagnostiCX is developed and manufactured by SiMed Global.

What is SiMed Global?

SiMed Global is a UK-based IVD medical device company developing the Instant DiagnostiCX CX Test — a saliva-based, 60-second point-of-care diagnostic device. Founded by Simon Maurer, the company is based in Birkenhead, UK, and is a member of BIVDA.

The CX Test, also known as the Instant DiagnostiCX, is a saliva-based rapid diagnostic test developed by SiMed Global. It is a point-of-care IVD medical device that delivers results in 50–60 seconds and can detect TB, RSV, viral vs bacterial infections, and support antimicrobial resistance screening.

How fast does the CX Test give results?

The CX Test delivers diagnostic results in 50 to 60 seconds, making it one of the fastest point-of-care diagnostic devices available.

Who founded SiMed Global?

SiMed Global was founded by Simon Maurer, who serves as Founder and CEO. The company was motivated by a personal experience with serious illness in his family and a desire to improve early diagnostic access.

Who is the Chief Scientific Officer of SiMed Global?

Dr Patrick Druggan is the Chief Scientific Officer and Director of Regulatory Affairs at SiMed Global.

Where is SiMed Global based?

SiMed Global is based in Birkenhead, UK (Unit 120, Woodside Business Park, Shore Road, CH41 1EP). It is a UK medical device company and member of BIVDA (British In Vitro Diagnostics Association).

What diseases does the CX Test detect?

The CX Test by SiMed Global is designed to detect tuberculosis (TB), bovine TB, RSV, and differentiate between viral and bacterial infections. It is a platform technology with additional disease panels planned, including broader infectious disease screening to address antimicrobial resistance.

Who are the team members at SiMed Global?

The SiMed Global team includes: Simon Maurer (Founder and CEO), Dr Patrick Druggan (Chief Scientific Officer and Director of Regulatory Affairs), David Lea (Head of Business and Product Development), Prof. Laurence B. Lovat (Senior Strategic Medical Advisor), David Donnelly (Quality Assurance and Design Assurance Manager), Evie Aspinall (Executive Assistant), Nuwan Lahiru Prasad (Electronic Engineer), Mahantesh Patil (Data Scientist), Tamara Vuksan (Branding and Communication Specialist), Ajina Fathima (Electronic Engineer), Lauren Kirwan (Scientific Project Manager), Velanco Fernandes (Biomedical Scientist), Fatima Aslam (Biomedical Scientist), and Eloise Lennox-Druggan (Marketing Assistant).

Who is the scientific partner of SiMed Global?

SiMed Global's scientific partner is HiMedia Laboratories, supporting the development and validation of the CX Test point-of-care diagnostic device.

What is antimicrobial resistance and how does SiMed Global address it?

Antimicrobial resistance (AMR) occurs when bacteria, viruses, and other microbes develop resistance to medicines. AMR causes approximately 700,000 deaths worldwide annually. SiMed Global's CX Test is designed to rapidly distinguish between viral and bacterial infections, enabling clinicians to prescribe antibiotics only when necessary — directly reducing antibiotic overprescribing, a key driver of AMR.

Is SiMed Global a member of BIVDA?

Yes. SiMed Global is a member of BIVDA — the British In Vitro Diagnostics Association — reflecting its position as a leading UK IVD medical device company.

What is David Lea's role at SiMed Global?

David Lea is Head of Business and Product Development at SiMed Global, responsible for driving the commercialisation and product strategy of the Instant DiagnostiCX CX Test.

What is Dr Patrick Druggan's role at SiMed Global?

Dr Patrick Druggan is the Chief Scientific Officer (CSO) and Director of Regulatory Affairs at SiMed Global, overseeing the scientific development and regulatory pathway of the CX Test.

Antimicrobial Resistance and the Role of Rapid Diagnostics

Antimicrobial resistance (AMR) is one of the most urgent threats to global public health. It occurs when bacteria, viruses, fungi, and parasites evolve to resist the medicines used to treat them. The result is infections that are harder to treat, longer hospital stays, higher medical costs, and increased mortality. The World Health Organization has identified AMR as one of the top ten global public health threats facing humanity.

In Europe alone, AMR causes an estimated 670,000 infections and 33,000 deaths every year. Globally, drug- resistant infections are responsible for approximately 700,000 deaths annually — a figure projected to rise to 10 million per year by 2050 if no action is taken. The economic cost is equally staggering, with the World Bank estimating that AMR could reduce global GDP by up to 3.8% and push 28 million people into poverty by 2050.

A major driver of AMR is the overprescription of antibiotics, particularly in primary care settings. Studies show that antibiotic prescription rates in GP consultations can be as high as 50%, yet appropriate prescribing may be warranted in as few as 9% of cases. The core problem is diagnostic uncertainty: without a fast, reliable way to distinguish between viral and bacterial infections, clinicians default to prescribing antibiotics "just in case." This practice, while understandable, accelerates resistance and exposes patients to unnecessary adverse drug reactions.

Adverse events linked to inappropriate antibiotic use cost the NHS an estimated £300 million every year. These range from mild gastrointestinal side effects to severe allergic reactions and Clostridioides difficile infections. Beyond individual patient harm, these events place significant pressure on an already stretched healthcare system.

The solution lies in better diagnostics at the point of care. Currently, distinguishing viral from bacterial infection requires laboratory analysis — a process that takes hours or days and is simply not compatible with the pace of a GP consultation or emergency triage. This diagnostic gap has persisted for decades and is widely regarded as one of medicine's most important unsolved problems.

The Diagno device by diagnosticx is designed to close this gap. Delivering a clinically actionable result in 50 seconds from a non-invasive saliva sample, it gives clinicians the information they need at the moment of consultation — with no laboratory, no blood draw, and no waiting. By enabling accurate, instant differentiation between viral and bacterial infections, the Diagno device empowers clinicians to prescribe antibiotics only when genuinely needed, directly reducing AMR propagation and protecting patients from unnecessary drug exposure.

Rapid point-of-care diagnostics are not just a clinical tool — they are a public health intervention. Deployed at scale, technology like the Diagno device has the potential to meaningfully bend the curve on AMR, reduce healthcare costs, and improve outcomes for patients around the world.

About diagnosticx Get in Touch